Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001193125-22-273298
Filing Date
2022-10-31
Accepted
2022-10-31 08:45:56
Documents
15
Period of Report
2022-10-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A d395338d8ka.htm   iXBRL 8-K/A 49419
2 EX-10.1 d395338dex101.htm EX-10.1 97133
3 EX-10.2 d395338dex102.htm EX-10.2 124222
4 EX-10.3 d395338dex103.htm EX-10.3 93216
  Complete submission text file 0001193125-22-273298.txt   584036

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA tsha-20221021.xsd EX-101.SCH 2517
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE tsha-20221021_lab.xml EX-101.LAB 19521
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tsha-20221021_pre.xml EX-101.PRE 12217
9 EXTRACTED XBRL INSTANCE DOCUMENT d395338d8ka_htm.xml XML 4105
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

EIN.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-39536 | Film No.: 221343899
SIC: 2836 Biological Products, (No Diagnostic Substances)